Financials Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/01/2026 GMT			5-day change	1st Jan Change
31.56 ^USD	-7.88%		+1.09%	+13.85%

01-14	Beam Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 05:15 PM
01-12	Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise	MT

Projected Income Statement: Beam Therapeutics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	0.024	51.84	60.92	377.7	63.52	38.7	44.67	66.8
Change	-	215,916.67%	17.51%	520.01%	-83.18%	-39.07%	15.42%	49.54%
EBITDA ¹	-	-385	-324.3	-156.5	-393.6	-470.7	-502.7	-527.4
Change	-	-	15.76%	51.76%	-151.57%	-19.58%	-6.79%	-4.93%
EBIT ¹	-132.8	-392.5	-338.5	-176.5	-415.6	-493.4	-538.6	-575
Change	-	-195.62%	13.76%	47.86%	-135.47%	-18.73%	-9.15%	-6.76%
Interest Paid	-	-	-	46.68	-	-	-	-
Earnings before Tax (EBT) ¹	-194.6	-370.6	-260.2	-131.2	-376.7	-395	-490.2	-536
Change	-	-90.47%	29.8%	49.59%	-187.21%	-4.85%	-24.1%	-9.35%
Net income ¹	-195.9	-370.6	-289.1	-132.5	-376.7	-402.5	-493.3	-536
Change	-	-89.23%	22%	54.16%	-184.28%	-6.83%	-22.57%	-8.67%
Announcement Date	15/03/21	28/02/22	28/02/23	27/02/24	25/02/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	0.006	0.006	0.006	0.763	51.07	8.432	16.65	15.8	20.04	24.21	20.12	17.19	316.2	7.41	11.77	14.27	30.07	7.47	8.466	9.698	13.22	13.75	13.85	13.95	14.64
Change	-	0%	0%	12,616.67%	6,593.18%	-83.49%	97.49%	-5.12%	26.82%	20.82%	-16.9%	-14.53%	1,739.07%	-97.66%	58.87%	21.21%	110.72%	-75.16%	13.33%	14.55%	36.27%	4.02%	0.74%	0.73%	4.96%
EBITDA ¹	-	-	-	-	-60.85	-72.91	-	-87.83	-85.04	-	-97.33	-103.1	138.2	-98.7	-99.32	-101	-94.59	-113.8	-114.6	-121.3	-114.6	-133	-136.5	-140	-
Change	-	-	-	-	-	-19.82%	-	-	3.18%	-	-	-5.91%	234.09%	-171.41%	-0.63%	-1.72%	6.37%	-20.26%	-0.75%	-5.79%	5.51%	-16.13%	-2.59%	-2.59%	-
EBIT ¹	-40.8	-200.4	-58.97	-69.63	-63.48	-76.22	-81.97	-91.3	-88.98	-98.93	-102.1	-108.3	132.9	-104.1	-104.9	-106.5	-100	-119.3	-120.2	-126.8	-126.4	-131.9	-134.2	-138	-138
Change	-	-391.12%	70.57%	-18.08%	8.83%	-20.07%	-7.53%	-11.39%	2.54%	-11.17%	-3.25%	-5.99%	222.71%	-178.38%	-0.73%	-1.53%	6.07%	-19.24%	-0.73%	-5.54%	0.33%	-4.38%	-1.75%	-2.79%	-0.04%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-95.46	-201.6	-76.25	-28.12	-64.71	-69.21	-71.95	-81.66	-37.35	-96.46	-82.78	-96.09	144.2	-98.67	-91.01	-96.67	-90.35	-109.3	-102.3	-112.7	-89.86	-121.1	-123.6	-129.2	-132.1
Change	-	-111.14%	62.17%	63.13%	-130.13%	-6.97%	-3.95%	-13.5%	54.27%	-158.27%	14.19%	-16.08%	250.03%	-168.44%	7.76%	-6.21%	6.53%	-20.94%	6.39%	-10.2%	20.29%	-34.75%	-2.04%	-4.58%	-2.27%
Net income ¹	-95.46	-201.6	-76.25	-28.12	-64.71	-69.21	-71.95	-109.6	-38.35	-96.46	-82.78	-96.09	142.8	-98.67	-91.05	-96.67	-90.35	-109.3	-102.3	-112.7	-92.86	-121.1	-123.6	-129.2	-132.1
Change	-	-111.14%	62.17%	63.13%	-130.13%	-6.97%	-3.95%	-52.29%	65%	-151.53%	14.19%	-16.08%	248.61%	-169.1%	7.72%	-6.17%	6.53%	-20.94%	6.39%	-10.2%	17.63%	-30.39%	-2.04%	-4.58%	-2.27%
Announcement Date	15/03/21	11/05/21	10/08/21	08/11/21	28/02/22	09/05/22	09/08/22	07/11/22	28/02/23	10/05/23	08/08/23	08/11/23	27/02/24	07/05/24	06/08/24	05/11/24	25/02/25	06/05/25	05/08/25	04/11/25	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Beam Therapeutics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-292	-960	-1,078	-1,190	-	-1,286	-891	-1,162
Change	-	-228.77%	-12.29%	-10.39%	-	-	30.72%	-30.42%
Announcement Date	15/03/21	28/02/22	28/02/23	27/02/24	25/02/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Beam Therapeutics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	16.36	46.81	48.95	33.73	8.946	13.88	18.5	19.56
Change	-	186.18%	4.57%	-31.09%	-73.48%	55.11%	33.33%	5.71%
Free Cash Flow (FCF) ¹	-112.1	-113.1	-26.42	-182.9	-356.2	-268.9	-371	-364.9
Change	-	-0.88%	76.63%	-592.28%	-94.72%	24.51%	-37.98%	1.63%
Announcement Date	15/03/21	28/02/22	28/02/23	27/02/24	25/02/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Beam Therapeutics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-742.64%	-532.39%	-41.43%	-619.73%	-1,216.2%	-1,125.21%	-789.56%
EBIT Margin (%)	-553,166.67%	-757.01%	-555.61%	-46.73%	-654.25%	-1,274.83%	-1,205.56%	-860.7%
EBT Margin (%)	-810,800%	-714.91%	-427.08%	-34.73%	-593.06%	-1,020.44%	-1,097.2%	-802.35%
Net margin (%)	-816,120.83%	-714.91%	-474.54%	-35.09%	-593.13%	-1,039.82%	-1,104.18%	-802.42%
FCF margin (%)	-467,075%	-218.11%	-43.37%	-48.43%	-560.77%	-694.7%	-830.47%	-546.3%
FCF / Net Income (%)	57.23%	30.51%	9.14%	138.03%	94.55%	66.81%	75.21%	68.08%
Profitability
ROA	-64.45%	-38.49%	-20.53%	-11.69%	-29.39%	-39.06%	-47.69%	-66.9%
ROE	-881.16%	-69.13%	-37.06%	-15.46%	-43.94%	-46.28%	-67.4%	-100.86%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	68,154.17%	90.29%	80.35%	8.93%	14.08%	35.85%	41.41%	29.28%
CAPEX / EBITDA (%)	-	-12.16%	-15.09%	-21.56%	-2.27%	-2.95%	-3.68%	-3.71%
CAPEX / FCF (%)	-14.59%	-41.4%	-185.25%	-18.44%	-2.51%	-5.16%	-4.99%	-5.36%
Items per share
Cash flow per share ¹	-	-1.032	0.3217	-1.934	-4.219	-3.849	-3.225	-
Change	-	-	131.18%	-701.12%	-118.15%	8.76%	16.23%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	5.255	12.87	10.7	12.72	8.771	11.58	7.192	8.036
Change	-	144.97%	-16.91%	18.93%	-31.04%	32.03%	-37.89%	11.72%
EPS ¹	-4.19	-5.77	-4.13	-1.72	-4.58	-4.277	-4.633	-4.589
Change	-	-37.71%	28.42%	58.35%	-166.28%	6.61%	-8.32%	0.95%
Nbr of stocks (in thousands)	56,474	66,849	68,821	79,326	79,592	98,693	98,693	98,693
Announcement Date	15/03/21	28/02/22	28/02/23	27/02/24	25/02/25	-	-	-